BioCentury
ARTICLE | Company News

Kura licenses J&J's tipifarnib, raises $60M

March 13, 2015 1:33 AM UTC

Kura Oncology Inc. (La Jolla, Calif.) licensed a cancer compound from the Janssen Pharmaceutica NV unit of Johnson & Johnson (NYSE:JNJ), reverse-merged with shell company Zeta Acquisition Corp. III and raised $60 million in a private placement.

Janssen granted Kura exclusive rights to develop and commercialize tipifarnib in oncology. Kura plans to start a Phase II trial of the farnesyl transferase inhibitor to treat solid tumors expressing HRAS mutations in 2Q15 and a Phase II trial to treat relapsed or refractory peripheral T cell lymphoma in 3Q15. ...